Mesa Laboratories, Inc.

What they do

Mesa designs and manufactures consumables and hardware, plus services like calibration and sterility assurance testing, for regulated applications. It operates in four divisions: Sterilization and Disinfection Control (SDC), Biopharmaceutical Development (BPD), Calibration Solutions (CS), and Clinical Genomics (CG). Products are sold directly in North America, Europe, and APAC and via distributors elsewhere. Manufacturing sites are in the U.S. and Europe.

Revenue drivers

• Sterilization and Disinfection Control (SDC) — Largest segment, 41% of 1Q27 revenues ($24.5M). Sells biological, chemical, and cleaning indicators and sterility assurance services; 1Q27 organic revenue declined 3.6% due to fulfillment and delivery issues.
• Calibration Solutions (CS) — 20% of 1Q27 revenues ($13.3M). Grew organic revenue 7.6% (core 7.5%) in 1Q27, the strongest growth among segments.
• Biopharmaceutical Development (BPD) — 20% of 1Q27 revenues ($12.1M). Organic revenue grew 5.0% on higher immunoassay hardware and consumables volumes plus price increases.
• Clinical Genomics (CG) — 17% of 1Q27 revenues ($10.3M). Organic revenue was essentially flat (-0.1%) versus prior year.

Recent performance

FY2026 (ended March 31, 2026) revenue was $249.1M, up from $241.0M in FY2025; net income turned positive to $6.7M from a -$2.0M loss. In Q1 FY2027 (June 30, 2026), revenue rose 1.0% to $60.1M; operating income jumped 129% to $7.0M, but net income fell 40.3% to $2.8M, due to a nonoperating expense versus an unrealized FX gain in the prior year. Adjusted operating income (excluding unusual items) rose 19.5% to $15.4M, a 25.6% margin. The company repaid $8.7M of debt, lowering net leverage to 1.85.

Strategy

Mesa's stated purpose is 'Protecting the Vulnerable' and it grows both organically and through acquisitions, focusing on complementing existing portfolios and expanding into life sciences tools and quality control markets. Management uses the 'Mesa Way' lean system to improve manufacturing, commercial, and administrative efficiency. In Q1 FY2027, new CEO Siddhartha Kadia said he is focused on disciplined execution and consistent, profitable growth across all four divisions, and has begun fixing 'fixable execution problems.' The company increased investment in SDC to support future organic growth while maintaining disciplined capital allocation and preserving financial flexibility.

Risks

• Economic and market sensitivity — Demand is affected by capital spending in pharmaceutical, healthcare, and medical device industries; elevated interest rates and reduced capex could hurt revenue.
• Tariffs and trade policy — Changes in trade policies, including tariffs, could raise input costs or disrupt supply chains; the company may not always pass costs through to customers.
• Execution and fulfillment issues — SDC suffered a 3.6% organic revenue decline in 1Q27 due to fulfillment and delivery challenges, which could recur and impact customer relationships.
• Integration and acquisition risk — Failure to consummate or integrate acquisitions at expected rates could impair growth and profitability; management acknowledges this risk in forward-looking statements.

Outlook

Management did not provide full-year guidance; CEO Kadia plans to issue guidance in November alongside first-half results. He stated the company has 'durable, regulation-embedded franchises' and is addressing execution issues. Q1 results exceeded expectations on adjusted operating margin, and the company is focused on debt repayment and maintaining leverage below its target of 2.0x. Continued positive core organic growth is expected, driven by CS and BPD while SDC investment ramps.